Get notified when MCRB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsCritical incident detected
Existential event
Time-sensitive event — see the red-flag panel below for the source-quoted detail.
Red Flags Detected
- Going Concern (worsened) — Substantial doubt about ability to continue as going concern persists; cash runway extended to Q3 2026 but additional funding required thereafter.
Seres pauses SER-155 Phase 2, pivots to inflammatory diseases, cuts 56% of workforce
Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 13, 2025 · ~2 min read
Key Changes
-
high
Company paused SER-155 Phase 2 investment in allo-HSCT after completing protocol submission and manufacturing, now seeking external funding to restart. Strategic focus shifted to inflammatory/immune diseases (IBD, checkpoint-inhibitor toxicity).
Business: SER-155 Phase 2 pause & I&I pivot verify on EDGAR → -
high
Headcount reduced from 103 employees (Dec 2024) to 45 (March 2026), a 56% cut. R&D staff fell from 76 to 32. Reductions reflect paused programs and strategic reorientation.
Business: Headcount reduction verify on EDGAR → -
high
Received $75M in milestone payments from Nestlé (Jan/July 2025), extending cash runway from Q1 2026 to Q3 2026. Going-concern qualification persists; company actively seeking partnerships to fund SER-155.
MD&A: Cash position & funding runway verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade MCRB commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify